| Paris | |
| 0 | |
| Biotech company dedicated to the discovery and development of drugs which regulate the immune system in autoimmune disease, transplantation and cancer immunotherapy. | |
| The 1st product-candidate, called FR104, resulting from companys research platform is currently in clinical Phase I trial in transplantation and rheumatoid arthritis in the frame of a licensing agreement with Janssen Biotech Inc. FR104 is a monovalent antibody fragment antagonist of the T-cell costimulator CD28. FR104 tips the balance of the immune response towards a pro-tolerogenic response and therefore provides a long-lasting pharmacological effect that has been demonstrated in preclinical models of organ and bone marrow transplantation, multiple sclerosis and rheumatoid arthritis. | |
| VANHOVE Bernard | |
| www.effimune.com | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 4 fois.